News | October 19, 2009

RenalGuard Demonstrated in Live Case at GISE 2009

October 19, 2009 – PLC Systems Inc. today said its RenalGuard System will be utilized as part of a live case transmission from the Clinica Mediterranea, Naples, Italy, to the 30th Congresso Nazionale della Societa' Italiana di Cardiologia Invasiva (GISE), Oct. 20-23, in Bologna, Italy.

Dr. Carlo Briguori, chief of the laboratory of interventional cardiology, Clinica Mediterranea, a noted expert on CIN, is currently conducting an investigator-sponsored multicenter randomized clinical trial on the efficacy of RenalGuard at his hospital. He plans to make a presentation on the status of his study at GISE, and will include a video demonstrating the use of RenalGuard during his talk.

This live case transmission marks the second time RenalGuard has been utilized as part of a live case transmission during a cardiac procedure during a cardiology conference. In May 2009, RenalGuard was included as part of a live case transmission from Hospital Clinico San Carlos, Madrid, Spain, during the meeting of EuroPCR. The interventional cardiologists involved in that case demonstrated how RenalGuard is used to help prevent contrast-induced nephropathy (CIN) in a patient with impaired renal function undergoing a percutaneous coronary intervention (PCI).

Preliminary data from the first investigator-sponsored randomized clinical trial of RenalGuard, known as MYTHOS, has been presented at two international cardiology conferences, and indicates that patients at high risk for renal failure, when treated with RenalGuard while undergoing certain imaging procedures, acquired CIN at a significantly lower rate than those who were treated with overnight hydration. Acquiring CIN has been found to lead to a range of serious and potentially deadly outcomes in patients who already have compromised kidney function.

The investigators for this trial are Dr. Antonio L. Bartorelli, director, interventional cardiology, CCM, and professor of cardiology, University of Milan, and Dr. Giancarlo Marenzi, chief, intensive cardiac care unit at CCM, two of the world's leading experts on CIN.

For more information: www.plcmed.com

Related Content

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
Overlay Init